224 related articles for article (PubMed ID: 33148061)
41. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
[TBL] [Abstract][Full Text] [Related]
42. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
[TBL] [Abstract][Full Text] [Related]
43. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.
Kullenberg T; Löfqvist M; Leinonen M; Goldbach-Mansky R; Olivecrona H
Rheumatology (Oxford); 2016 Aug; 55(8):1499-506. PubMed ID: 27143789
[TBL] [Abstract][Full Text] [Related]
44. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
45. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
Mallalieu NL; Wimalasundera S; Hsu JC; Douglass W; Wells C; Penades IC; Cuttica R; Huppertz HI; Joos R; Kimura Y; Milojevic D; Rosenkranz M; Schikler K; Constantin T; Wouters C
Pediatr Rheumatol Online J; 2019 Aug; 17(1):57. PubMed ID: 31438986
[TBL] [Abstract][Full Text] [Related]
46. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
Brunner HI; Quartier P; Alexeeva E; Constantin T; Koné-Paut I; Marzan K; Schneider R; Wulffraat NM; Chasnyk V; Tirosh I; Kallinich T; Kuemmerle-Deschner J; Wouters C; Lauwerys B; Nikishina I; Trachana M; Vougiouka O; Martini A; Lovell DJ; Levy J; Vritzali E; Ruperto N;
Arthritis Rheumatol; 2020 Dec; 72(12):2147-2158. PubMed ID: 32648697
[TBL] [Abstract][Full Text] [Related]
48. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.
Kearsley-Fleet L; Davies R; Baildam E; Beresford MW; Foster HE; Southwood TR; Thomson W; Hyrich KL
Rheumatology (Oxford); 2016 Sep; 55(9):1556-65. PubMed ID: 26732349
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.
Kuemmerle-Deschner JB; Tyrrell PN; Koetter I; Wittkowski H; Bialkowski A; Tzaribachev N; Lohse P; Koitchev A; Deuter C; Foell D; Benseler SM
Arthritis Rheum; 2011 Mar; 63(3):840-9. PubMed ID: 21360513
[TBL] [Abstract][Full Text] [Related]
50. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis.
Klein A; Minden K; Hospach A; Foeldvari I; Weller-Heinemann F; Trauzeddel R; Huppertz HI; Horneff G
Ann Rheum Dis; 2020 Jul; 79(7):969-974. PubMed ID: 32299797
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
52. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.
Klotsche J; Raab A; Niewerth M; Sengler C; Ganser G; Kallinich T; Niehues T; Hufnagel M; Thon A; Hospach T; Horneff G; Minden K
Arthritis Rheumatol; 2016 Dec; 68(12):3023-3034. PubMed ID: 27332999
[TBL] [Abstract][Full Text] [Related]
53. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.
Janow G; Schanberg LE; Setoguchi S; Hasselblad V; Mellins ED; Schneider R; Kimura Y;
J Rheumatol; 2016 Sep; 43(9):1755-62. PubMed ID: 27307527
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
[TBL] [Abstract][Full Text] [Related]
55. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.
Moltó A; Ea HK; Richette P; Bardin T; Lioté F
Joint Bone Spine; 2012 Dec; 79(6):621-3. PubMed ID: 22658375
[TBL] [Abstract][Full Text] [Related]
57. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
Strangfeld A; Hierse F; Rau R; Burmester GR; Krummel-Lorenz B; Demary W; Listing J; Zink A
Arthritis Res Ther; 2010; 12(1):R5. PubMed ID: 20064207
[TBL] [Abstract][Full Text] [Related]
58. Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis.
Pardeo M; Rossi MN; Pires Marafon D; Sacco E; Bracaglia C; Passarelli C; Caiello I; Marucci G; Insalaco A; Perrone C; Tulone A; Prencipe G; De Benedetti F
Arthritis Rheumatol; 2021 Jun; 73(6):1053-1061. PubMed ID: 33615724
[TBL] [Abstract][Full Text] [Related]
59. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study.
Sozeri B; Demir F; Barut K; Atalay E; Pac Kisaarslan A; Özdel S; Altuğ Gücenmez Ö; Makay B; Aktay Ayaz N; Haşlak F; Sağ E; Yıldız M; Kaya Akça Ü; Adroviç A; Bilginer Y; Poyrazoğlu H; Ünsal E; Kasapçopur Ö; Özen S
Clin Exp Rheumatol; 2024 Jan; 42(1):194-201. PubMed ID: 37497697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
